LogicBio Therapeutics, Inc. (LOGC) Financial Statements (2024 and earlier)

Company Profile

Business Address 65 HAYDEN AVE
LEXINGTON, MA 02421
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments38,84642,73953,48059,58168,10863,942
Cash and cash equivalents38,84642,73953,48059,58168,10863,942
Receivables   301197789
Other undisclosed current assets1,9402,4772,1569851,8392,096
Total current assets:40,78645,21655,66660,68570,02466,127
Noncurrent Assets
Operating lease, right-of-use asset3,9954,2864,5714,8515,1265,395
Property, plant and equipment1,6141,7751,9112,0282,1031,780
Restricted cash and investments622622622622622622
Total noncurrent assets:6,2316,6837,1047,5017,8517,797
TOTAL ASSETS:47,01751,89962,77068,18677,87573,924
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,8113,8854,4224,3694,8694,723
Employee-related liabilities766623   881
Accounts payable1,2571,4987189031,256709
Accrued liabilities1,7881,7643,7043,4663,6133,133
Deferred revenue10,4408,69410,6394,8374,843 
Debt3,3023,2983,2953,2913,288 
Other liabilities 8392   334
Other undisclosed current liabilities4495471,2271,1931,1592,646
Total current liabilities:18,08516,51619,58313,69014,1597,703
Noncurrent Liabilities
Long-term debt and lease obligation6,4877,6148,7319,83610,92911,996
Long-term debt, excluding current maturities3,4244,2175,0065,7906,5687,337
Liabilities, other than long-term debt1,7292,8583,7295,8967,967 
Deferred revenue1,7292,8583,7295,8967,967 
Operating lease, liability3,0633,3973,7254,0464,3614,659
Other undisclosed noncurrent liabilities      (4,659)
Total noncurrent liabilities:8,21610,47212,46015,73218,89611,996
Total liabilities:26,30126,98832,04329,42233,05519,699
Equity
Equity, attributable to parent20,71624,91130,72738,76444,82054,225
Common stock333333
Additional paid in capital172,439171,590170,744169,718165,589164,495
Accumulated deficit(151,726)(146,682)(140,020)(130,957)(120,772)(110,273)
Total equity:20,71624,91130,72738,76444,82054,225
TOTAL LIABILITIES AND EQUITY:47,01751,89962,77068,18677,87573,924

Income Statement (P&L) ($ in thousands)

9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
Revenues3,1992,8162,0272,120802461
Gross profit:3,1992,8162,0272,120802461
Operating expenses(8,091)(9,265)(10,832)(12,063)(11,022)(10,478)
Operating loss:(4,892)(6,449)(8,805)(9,943)(10,220)(10,017)
Nonoperating expense(152)(213)(258)(270)(279)(265)
Interest and debt expense(197)(218)(246)(270)(283)(271)
Loss from continuing operations before equity method investments, income taxes:(5,241)(6,880)(9,309)(10,483)(10,782)(10,553)
Other undisclosed income from continuing operations before income taxes  246270283271
Loss from continuing operations before income taxes:(5,241)(6,880)(9,063)(10,213)(10,499)(10,282)
Income tax benefit    28  
Loss from continuing operations:(5,241)(6,880)(9,063)(10,185)(10,499)(10,282)
Loss before gain (loss) on sale of properties:(5,241)(6,880)(9,063)(10,185)(10,499)(10,282)
Other undisclosed net income  218    
Net loss:(5,241)(6,662)(9,063)(10,185)(10,499)(10,282)
Other undisclosed net income attributable to parent 197     
Net loss available to common stockholders, diluted:(5,044)(6,662)(9,063)(10,185)(10,499)(10,282)

Comprehensive Income ($ in thousands)

9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
Net loss:(5,241)(6,662)(9,063)(10,185)(10,499)(10,282)
Comprehensive loss:(5,241)(6,662)(9,063)(10,185)(10,499)(10,282)
Other undisclosed comprehensive income, net of tax, attributable to parent 197     
Comprehensive loss, net of tax, attributable to parent:(5,044)(6,662)(9,063)(10,185)(10,499)(10,282)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: